KR20010102650A - Composition comprising extract of medicinal herbs for treating behcet's disease - Google Patents

Abstract

The present invention relates to a composition for treating Behcet's disease containing herbal extracts, as active ingredients, Baekjak, Angelica, Baekchul, Hwanggi, Injin, Geumeunhwa, Hojanggeun, Choyongdam, Siho, Yeongyo, Hyunsam, Sanchija, Pogongyoung, Hwangyeon The present invention relates to a composition for treating Behcet's disease, which comprises, in combination with a pharmaceutically acceptable carrier, an extract of one species selected from the group consisting of golden, yellow and yellow white extracts.

Description

Composition comprising extract of medicinal herbs for treating Behcet's disease

The present invention relates to a composition for treating Behcet's disease, and more particularly, as an active ingredient, Baekjak, Angelica, Baekchul, Hwanggi, Injin, Geumeunhwa, Hojanggeun, Choyongdam, Siho, Yeongyo, Hyunsam, Sanchija, Pogongyoung, Hwangyeon, The present invention relates to a composition for treating Behcet's disease, which contains an extract of one species selected from the group consisting of golden and yellow white extracts together with a pharmaceutically acceptable carrier.

In general, Behcet's disease is one of the most threatening diseases in countries around Asia and the Mediterranean, including Japan, Korea, and China, and is an inflammatory disease that affects many organs, including the eye. Treatment of patients with Behcet's disease progressed in several ways. These treatments include local, systemic or medical treatments, but they have not achieved satisfactory results. Several experiments have shown that immunological changes play an important role in the pathogenesis of Behcet's disease. Immune changes seen in Behcet's disease include T cell activity and abnormal function of white blood cells. Immunologically, mucosal lesions first penetrate CD4, CD8 cells, macrophages and dendritic cells, and then neutrophils. Because immunological processes are involved in a series of developments of Behcet's disease, several drugs that modulate the immune response have been used to treat Behcet's disease. These agents include corticosteroids, colchicine, cytotoxic agents and immunophilin ligands such as cyclosporin and the like. However, these drugs have a problem that can cause severe side effects when used for a long time.

Therefore, the inventors of the present invention needed to develop a composition comprising herbal extracts useful for treating Behcet's disease using an animal model developed by the present inventors.

The present invention solves the problems as described above, and the object of the present invention is to provide a composition for treating Behcet's disease.

In order to achieve the above object, the present invention is the group consisting of Baekjak, Angelica, Baekchul, Hwanggi, Injin, Geumeunhwa, Hojanggeun, Choyongdam, Siho, Yeongyo, Hyunsam, Sanchija, Pogongyoung, Hwangyeon, Golden and Yellow White Extract as active ingredients. Provided is a composition for treating Behcet's disease containing at least one extract selected from a pharmaceutically acceptable carrier.

It is more preferable that the said composition contains colchicine.

On the other hand, colchicine (hereinafter referred to as "col") used in the present invention may have side effects such as diarrhea and decreased sperm count when administered in a dose of 1.8 micrograms or more for 60 g mice. Since there is little effect, it is preferable to administer 0.6-1.8 µg daily to 60 g mice.

Herbal medicine extract used in the present invention is extracted by using a solvent extracting solvent, preferably one solvent selected from purified water, ethanol, methanol, butanol, ethyl acetate and acetone, and filtered and used as an extract.

In addition, the composition of the present invention may further include conventionally used excipients, disintegrants, sweeteners, lubricants, flavoring agents, etc., tablets, capsules, powders, granules, suspensions, emulsifiers, It may be formulated as a pharmaceutical formulation for single or multiple administration, such as a syrup, liquid or parenteral formulation.

The composition of the present invention can be parenterally administered or orally administered as desired, and the effective amount of the herbal extract of the present invention is 8 mg for Herbal Medicine 1, 6 mg for Herbal Medicine 2, 6 mg for Herbal Medicine 3, 3.6 for Herbal Medicine 3.6 Long-term administration of more than mg may cause the spleen of the mouse to become large, and at low concentrations of 0.08 mg for herbal 1, 0.06 mg for herbal 2, 0.06 mg for herbal 3, and 0.036 mg for herbal 4 Since it is difficult, 0.036-8 mg per day is preferable for 60 g of body weight, and can be administered over 1 to several times. The dosage level for a particular patient may vary depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, severity of disease, and the like.

EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.

The pathogenesis of Behcet's disease has been claimed in many ways. 1937 Since Dr. Behcets's insistence on viral theories, genetics suggest that infections caused by streptococci, and those with HLA-B51 have a high incidence, 311- of mycobacteria '65kD heat shock protein 60 degrees homology between 326 peptide and human 60kD heat shock protein 336-351 peptide means that immunologically related substances such as stress proteins and heat shock proteins act as immune response proteins, environmental pollutants such as pesticides The onset of the disease. Yet one of these theories does not fully explain the development of Behcet's disease. Several research groups have attempted to build animal models of Behcet's disease using experimental animals. The first reported animal is a miniature swine fed with environmental contaminants. HLA-B51 transgenic mice were then reported, and Lewis rats injected with heat shock protein peptide fragments were reported. Finally, ICR mice inoculated with herpes simplex virus (HSV) were developed and reported by our team. The earpick of the ICR mouse was scratched with a needle to injure the wound, and the site was inoculated twice with the virus at four week intervals. The symptoms of Behcet's disease in about 30 mice were not only blisters and skin crusts, but also mouth ulcers, vulvar ulcers, skin ulcers, eye symptoms, joint symptoms, gastrointestinal involvement, and nervous system involvement. It showed a recurrent feature that improved naturally and then worsened. Histological examination showed that many inflammatory cells accumulate around the blood vessels, which is typical of histology.

Recently, a Behcet's disease animal model has been developed by inoculating herpes simplex virus into a wound ear canal of an ICR mouse. In this mouse model, the main symptoms such as oral ulcer, vulvar ulcer, skin ulcer, and eye symptoms appear in human patients, and minor symptoms such as gastrointestinal ulcer and arthritis.

The inventors of the present invention was administered to the animal model mice in combination with four herbal medicines and colchicine, a main drug of Behcet's disease, to treat Behcet's disease animal model.

The inventors of the present invention include the following groups: I) oral administration of herbal medicine, oral administration of colchicine, oral administration of herbal medicine + colchicine, II) oral administration of herbal medicine in animal models of Behcet's disease symptoms, oral administration of colchicine, oral administration of herbal medicine + colchicine The proceed was divided.

Symptoms of Behcet's Disease In order to determine the mechanism of action of Behcet's disease in mice whose symptoms improve after administration among animals, IL-4, IL-10 and IFN-γ cytokines were analyzed by FACS analysis on splenocytes of mice. Changes in the amount of protein expressed in the cells of Caine were investigated, and RNA was extracted to detect the expression of T helper cytokines in the spleens of the mice. IL-4, IL-10, IL-12, IFN-γ RT-PCR on cytokines was performed to confirm the expression of Th1 / Th2 cytokines.

The experimental animal composition for Chinese medicine administration was: I) oral administration to normal mice, oral administration of colchicine, oral administration of herbal medicine + colchicine, II) oral administration of herbal medicine to animal models of Behcet's disease symptoms, oral administration of colchicine, oral administration of herbal medicine + colchicine The efficacy of Behcet's disease was evaluated by the combination of Herbal Medicines 1, 2, 3, and 4, and Herbal Medicine 2 + Colchicine, Herbal Medicine 3 + Colchicine, Herbal Medicine 4 + Colchicine.

In the composition of Chinese medicine, Bechette 1 (hereinafter referred to as "Chinese medicine 1") is the main medicine, Paeoniae radix alba, Angelicae gigantis radix, Atractylodis macrocephalae, Astragali radix, Injin (artemisiae capillaries) herba, lonicerae flos, poligoni cuspidate rhizoma, with gardenia (gardeniae fructus), forsythiae fructus, glycyrrhizae radix, cotidis rhizoma, sophorae tonkinensis radix),

Behcet 2 (hereinafter referred to as "Chinese medicine 2") is the main medicine, gentianae radix, bupleuri radix, forsythiae fructus, scrophulariae radix, gardenia (gardeniae fructus). Licorice (glycyrrhizae radix), peppermint (menthae herba), sophorae tonkinensis radix were used.

Behcet 3 (hereinafter referred to as "Chinese medicine 3") room was made of pogongyoung (taraxaci herba),

Behcet No. 4 (hereinafter referred to as “Chinese Herbs”) was made of Codydis Rhizoma, Scutellariae Radix, and Phellodendri Cortex.

Hereinafter, the present invention will be described in detail through non-limiting examples.

Example 1

1) As a component of Behcet 1-bang (Chinese medicine 1):

The main medicine is 4-16 g of paeoniae radix alba; 2-8 g of angelicae gigantis radix; 2-8 g of atractylodis macrocephalae; 2-8 g of assortali radix; 6-24 g of artemisiae capillaries herba; 5-20 g of lonicerae flos; 4-16 g of poligoni cuspidate rhizoma was used.

As a medicine, gardenia (gardeniae fructus), forsythiae fructus, glycyrrhizae radix, cotidis rhizoma, and sorae tonkinensis radix were used.

2) Preparation and Administration of Herbal Medicine 1

Three times of the total weight of the water was added and boiled by heating under reduced pressure for 2 to 4 hours, and the medicine was filtered, and the water was filtered again by adding 1.5 times of water and filtering. The first filtered drug and the second filtered drug were mixed and administered. One dose of 8 mg per mouse once a day was considered 100 doses.

Example 2

1) As a component of Behcet's 2 Room (Herbal Medicine 2):

Main medicines include 2-8 g of gentianae radix; Bupleuri radix 2-8 g; 2-8 g of forsythiae fructus; 2-8 g of scrophulariae radix; 1.5-6 g of gardenia (gardeniae fructus) was used,

Licorice (glycyrrhizae radix), peppermint (menthae herba), sophorae tonkinensis radix were used.

2) Preparation and Administration of Chinese Medicine 2

Add water three times the total weight of the medicine and boil by heating under reduced pressure for 2 to 4 hours, and then the medicine is filtered, and the water is filtered again by adding 1.5 times of water. The first filtered medicine and the second filtered medicine are mixed and administered. A dose of 6 mg per mouse once daily was considered 100 doses.

Example 3

Ingredients, Preparation and Administration of Behcet 3

250 g of taraxaci herba was extracted with water, dried, and then administered 6 mg once daily per mouse, which was considered 100 doses.

Example 4

Components, Preparations, and Administration of Behcet 4-Bang (Herbal Medicine 4):

120 g of Coptidis Rhizoma, Scutellariae Radix, and Phellodendri Cortex were mixed, extracted with water, and dried.

Example 5

Colchicine (hereinafter referred to as "col") was administered 1.2 micrograms per day to 60 g mice.

Example 6

The extract of Example 2 and colchicine were administered in combination to the same mouse. The amount of Chinese medicine 2 was 6 mg per mouse, and colchicine 1.2 micrograms, once daily administration of 100 mg was considered.

Example 7

Colchicine was mixed and administered to the extract of Example 3. Chinese medicine 3 was administered 6 mg once per mouse, and colchicine was considered to be 100 doses of 1.2 micrograms once daily.

Example 8

Colchicine was mixed and administered to the extract of Example 4. Herbal Medicine 4 was administered 3.6 mg once a day per mouse, colchicine was considered to be 100 doses administered once a day each 1.2 micrograms.

Example 9

RT-PCR, FACS Results:

After 20 days of oral administration of herbal, colchicine, and herbal + colchicine in Behcet's disease mice, RT-PCR in spleen tissue and FACS in splenocyte culture were examined.

[Table 1] Improvement of Behcet's Disease Mice by Combination with Chinese Medicine and Colchicine

Treatment Method (Improved / total Number of Rats) Rat Number ( Improved: o, Unchanged : x) BD, Herbal Medicine 1 (5/8) 263-3 (o), 280-3 (o), 287-1 (x), 305-3 (o), 315-4 (o), 332-3 (o), 332-4 (x), 333 -6 (x) BD, Herbal Medicine 2 (5/9) 252-3 (o), 273-5 (o), 306-4 (o), 331-1 (o), 335-3 (x), 336-1 (x), 336-2 (x), 337 -1 (o), 337-2 (x) BD, Chinese medicine 3 (2/3) 255-10 (o), 257-5 (x), 258-4 (o) BD, Chinese Medicine 4 (4/6) 257-5 (o), 265-9 (o), 275-4 (o), 280-5 (x), 312-5 (x), 314-5 (o) BD, col (1/3) 292-4 (x), 292-5 (o), 292-6 (x) BD, Han1 + col (2/3) 275-4 (x), 277-4 (o), 280-4 (o) BD, 2 + col (2/4) 268-9 (o), 285-6 (x), 303-7 (o), 307-4 (x) BD, Han3 + col (3/3) 264-5 (o), 270-6 (o), 276-4 (o) BD, Han 4 + col (2/3) 263-5 (o), 263-8 (x), 267-5 (o)

Taken together, the results in Table 1 show a higher tendency for Behcet's disease to improve in the Chinese and multi-administrated groups than in the coadministration alone.

[Table 2] Cytokine Changes in Behcet's Disease Mice by Combination with Chinese Medicine and Colchicine

Putting together the results of this table,

1) Herbs 3 and 4 have the effect of increasing the protein level of IL-10.

2) Colchicine has the effect of lowering the RNA level of TNF-α. On the other hand, TNF-α plays an important role in causing inflammation of Behcet's disease, so lowering this is good for improving symptoms.

3) Colchicine has the effect of raising the protein level of IL-4.

4) When herbal medicine 2 and colchicine are administered together, IFN-γ is lowered and IL-10 levels are increased.

[Table 3] Improvement of Symptoms Caused by Combination of Herbal Medicine and Colchicine

Treatment method Mouse number Symptom changes before and after drug administration Herbal Medicine 1 280-3 Facial blisters, gastrointestinal symptoms, earpick erythema (11/1) → Drug administration (11/1-) → Improvement of ear and facial blisters (11/4) → Gastrointestinal symptoms disappeared (11/29) → Sacrifice (11/22) 305-3 Facial blisters, oral ulcers (11/1) → Drug administration (11/1 ~) → Improvement (11/4) → Normal (11/7) → Sacrifice (11/22) Chinese medicine 2 252-3 Facial blister, nape ulcer (12/13), medicine administration → facial improvement, nape lasting (1/6) → sacrificial (1/6) 273-5 Facial blisters (9/13) → Facial blisters persist (10/7) → Continuous (11/18) → Facial ulcers (12/13) → Drug administration (12/13 to) → Improvement (12/22) → Sacrifice ( 12/22) 306-4 Neck ulcer (10/25) → Drug administration (10/25 ~) → Stop soreness, improvement (11/4) → Sacrifice (11/6) 331-1 Facial blisters, eye symptoms (10/22) → Drug administration (10/22-) → Eye symptoms improvement (10/29) → Facial improvement (11/4) → Sacrifice (11/4) 337-1 Left facial paralysis (10/18) → death (10/19) → gastrointestinal symptoms (10/22) → drug administration (10/22 ~) → deterioration (10/25) → ear ulcers (11/3) → Improvement (11/4) → Sacrifice (11/4) Chinese Medicine 3 255-10 Both ear canal ulcers, nape ulcer (11/29) → drug administration (11/29-) → improvement (12/6) → weight gain, left ear improvement, nape ulcer improvement, right ear improvement → sacrificing (11/4) 258-4 Left facial edema, skin ulcers (6/25) → facial blisters (11/1) → persistence of facial blisters (11/29) → drug administration (11/29 ~) → improvement of skin ulcers (12/13) → sacrificing (12 / 22) Chinese Medicine 4 257-5 Left anterior leg ulcer, facial ulcer (11/29) → Symptoms persist → Drug administration (12/27 ~) → Improvement (1/20) → Sacrifice (1/31) 265-9 Left earpick erythema (10/11) → Continuous (10/15) → Improvement of erythema, sore throat ulcer (11/29) → Drug administration (11/29 ~) → Improvement of ulcer, facial blister persist (12/27) → Sacrifice (12/27) 314-5 Bilateral ulcer ulcer, nape ulcer (11/29) → drug administration (11/29 ~) → improvement (12/6) → sacrificial (12/8) Colchicine 292-5 Back skin ulcers, facial blisters (11/1) → facial ulcers (11/18) → drug administration (11/18 ~) → improvement (12/6) → sacrifice (12/6)

Herbal Medicine 1 + Colchicine 277-4 Blisters, scabs, left ear canal erythema, ulcers (11/29) → drug administration (11/29-) → right eye improvement (12/6), left eye improvement (12/16) → sacrifice (12 / 17) 280-4 Facial blisters (9/30) → Facial blisters (10/7) → Skin ulcers (11/29) → Drug administration (11/18 ~) → Improvement (12/6) → Improvement (12/13) → Sacrifice (12 / 13) Herbal Medicine 2 + Colchicine 268-9 Facial blisters, back skin ulcers (11/29) → Drug administration (11/29-) → Almost complete healing → Sacrifice (12/8) 303-7 Both ear canal ulcers, facial blisters (11/29) → Drug administration (11/29-) → Both ear canal ulcers, improved facial blisters (12/6) → Improvement (12/13) → Sacrificial (12/13) Herbal Medicine 3 + Colchicine 264-5 Flank skin ulcers, skin ulcers around the right eye (12/13) → drug administration (12/13-) → improvement (12/22) → sacrificial (12/22) 270-6 Nape ulcer, bilateral earpick erythema, right earpick ulcer (12/13) → drug administration (12/13-) → nape ulcer improvement, bilateral earpick erythema improvement (12/20) 276-4 Facial blister, bilateral earpick erythema (11/29) → nape ulcer, left earpick ulcer (12/13) → drug administration (12/13 to) → ulcer size begins to decrease (12/16) Herbal Medicine 4 + Colchicine 263-5 Facial blisters (8/30), right eye ulcers (10/22) → Right eye symptoms, facial blisters (11/1) → right eye ulcers persist (11/29) → Drug administration (11/30 ~) → Under improvement (12/16) → Sacrifice (12/22) 267-5 Bilateral eye symptoms (7/28) → symptoms disappeared (8/19) → gastrointestinal symptoms (9/27) → facial blisters (10/15), gastrointestinal symptoms recovery → left ear canal ulcers, facial blisters (12/6) → medicine Administration (12/6 ~) → Increase (12/16) → Sacrifice (12/17)

Summarizing the results of Table 3, the duration of symptom improvement by 6 or 29 days of treatment with herbal or colchicine alone was 3 to 25 days. There was a tendency to accelerate the time, and the number of mice improved by multiple doses was higher than the single dose (see Table 1).

According to the present invention, the rate of Behcet's disease symptom is improved in the group administered with Chinese medicine and the group administered with colchicine alone. There was an effect of improving the symptoms of Behçet's disease, and the combination of Chinese medicine and colchicine accelerated the time of improvement, and the number of mice improved was higher than that of single treatment.

Claims (3)

As an active ingredient, an effective amount of Baekjak, Angelica, Baekchul, Astragalus, Injin, Geumhwa, Hojanggeun, Choyongdam, Siho, Yeongyo, Hyunsam, Sanchija, Pogongyoung, Hwangyeon, Golden and Yellow White Extract A composition for treating Behcet's disease, which is contained together with a pharmaceutically acceptable carrier. The method of claim 1, The composition of the Behcet's disease treatment, characterized in that it further comprises colchicine of 0.6 ~ 1.8㎛ / day in 60g body weight. The method according to claim 1 or 2, The effective amount of the herbal extract is a composition for treating Behcet's disease, characterized in that 0.036 to 8mg / day in 60g body weight.